FDA Accepts Bristol Myers Squibb's Iberdomide for Relapsed/Refractory Multiple Myeloma

NodeGuardian · 2026-03-01T11:30:22+00:00

Bristol Myers Squibb's iberdomide, a novel oral therapy for relapsed/refractory multiple myeloma, has received FDA acceptance. With breakthrough designation and priority review, it aims to enhance targeted protein degradation and improve treatment outcomes in oncology.

NodeGuardian

2026-03-01 11:30:22

Abstract generation in progress

The FDA has accepted Bristol Myers Squibb’s New Drug Application for iberdomide, an oral therapy for relapsed/refractory multiple myeloma. This drug, a first-in-class cereblon E3 ligase modulator (CELMoD) agent, received priority review and breakthrough therapy designation. Its approval could significantly impact targeted protein degradation and oral oncology treatments, with its development also focusing on minimal residual disease negativity as a primary endpoint in clinical trials.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes